Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
113634233 | 11363423 | 3 | F | 20150709 | 20150731 | 20150811 | 20160718 | EXP | US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2015-053676 | BRISTOL MYERS SQUIBB | 35.00 | YR | F | Y | 0.00000 | 20160718 | OT | US | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
113634233 | 11363423 | 1 | PS | ATAZANAVIR SULFATE | ATAZANAVIR SULFATE | 1 | Oral | 300 MG, QD | 11100 | MG | Y | 21567 | 300 | MG | QD | ||||
113634233 | 11363423 | 2 | SS | ATRIPLA | EFAVIRENZEMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 1100 MG, QD | 0 | 1100 | MG | FILM-COATED TABLET | QD | ||||||
113634233 | 11363423 | 3 | SS | ATRIPLA | EFAVIRENZEMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 1100 MG, QD | 0 | 1100 | MG | FILM-COATED TABLET | QD | ||||||
113634233 | 11363423 | 4 | SS | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 500 MG, QD | 18500 | MG | Y | 0 | 500 | MG | QD | ||||
113634233 | 11363423 | 5 | SS | NORVIR | RITONAVIR | 1 | Oral | 100 MG, QD | 3700 | MG | Y | 0 | 100 | MG | QD | ||||
113634233 | 11363423 | 6 | SS | STRIBILD | COBICISTATELVITEGRAVIREMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Oral | 800 MG, QD | 0 | 800 | MG | QD | |||||||
113634233 | 11363423 | 7 | SS | METRONIDAZOLE. | METRONIDAZOLE | 1 | Unknown | U | 0 | ||||||||||
113634233 | 11363423 | 8 | SS | NIFEDIPINE. | NIFEDIPINE | 1 | Unknown | U | 0 | ||||||||||
113634233 | 11363423 | 9 | SS | ONDANSETRAN | ONDANSETRON HYDROCHLORIDE | 1 | Unknown | U | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
113634233 | 11363423 | 1 | HIV infection |
113634233 | 11363423 | 2 | HIV infection |
113634233 | 11363423 | 4 | HIV infection |
113634233 | 11363423 | 5 | HIV infection |
113634233 | 11363423 | 6 | HIV infection |
113634233 | 11363423 | 7 | Product used for unknown indication |
113634233 | 11363423 | 8 | Product used for unknown indication |
113634233 | 11363423 | 9 | Product used for unknown indication |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
113634233 | 11363423 | OT |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
113634233 | 11363423 | Abortion induced | |
113634233 | 11363423 | Bacterial vaginosis | |
113634233 | 11363423 | Foetal death | |
113634233 | 11363423 | Maternal exposure during pregnancy |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
113634233 | 11363423 | 1 | 20150519 | 20150624 | 0 | |
113634233 | 11363423 | 2 | 20150519 | 0 | ||
113634233 | 11363423 | 3 | 20150625 | 0 | ||
113634233 | 11363423 | 4 | 20150519 | 20150624 | 0 | |
113634233 | 11363423 | 5 | 20150519 | 20150624 | 0 |